Read by QxMD icon Read


Judit Fazekas-Singer, Josef Singer, Kristina M Ilieva, Miroslawa Matz, Ina Herrmann, Edzard Spillner, Sophia N Karagiannis, Erika Jensen-Jarolim
Anti-cancer immunotherapies currently rely on IgG antibodies. In line with the AllergoOncology concept we provide evidence that tumor-specific IgE, alone or combined with IgG, may be superior to IgG treatment alone. The novel can225IgE-λ was made for future studies in dogs as translational model patients.
May 7, 2018: Journal of Allergy and Clinical Immunology
Kristina Johansson, Julie Weidner, Madeleine Rådinger
Type 2 immunity drives the pathology of allergic diseases and is necessary for expulsion of parasitic worms as well as having important implications in tumor progression. Over the last decade, a new research field has emerged describing a significant link between type 2 immunity and cancer development, called AllergoOncology. Thus, type 2 immune responses must be carefully regulated to mediate effective protection against damaging environmental factors, yet avoid excessive activation and immunopathology. Regulation of gene expression by microRNAs is required for normal behavior of most mammalian cells and has been studied extensively in the context of cancer...
March 28, 2018: Cancer Letters
Silvia Crescioli, Giulia Chiaruttini, Silvia Mele, Kristina M Ilieva, Giulia Pellizzari, Daniel I R Spencer, Richard A Gardner, Katie E Lacy, James F Spicer, Andrew N J Tutt, Gerd K Wagner, Sophia N Karagiannis
No abstract text is available yet for this article.
April 2018: Journal of Allergy and Clinical Immunology
E Jensen-Jarolim, H J Bax, R Bianchini, S Crescioli, T R Daniels-Wells, D Dombrowicz, E Fiebiger, H J Gould, S Irshad, J Janda, D H Josephs, F Levi-Schaffer, L O'Mahony, G Pellizzari, M L Penichet, F Redegeld, F Roth-Walter, J Singer, E Untersmayr, L Vangelista, S N Karagiannis
While desired for the cure of allergy, regulatory immune cell subsets and nonclassical Th2-biased inflammatory mediators in the tumour microenvironment can contribute to immune suppression and escape of tumours from immunological detection and clearance. A key aim in the cancer field is therefore to design interventions that can break immunological tolerance and halt cancer progression, whereas on the contrary allergen immunotherapy exactly aims to induce tolerance. In this position paper, we review insights on immune tolerance derived from allergy and from cancer inflammation, focusing on what is known about the roles of key immune cells and mediators...
February 2018: Allergy
Erika Jensen-Jarolim, Michelle C Turner, Sophia N Karagiannis
No abstract text is available yet for this article.
October 2017: Journal of Allergy and Clinical Immunology
E Jensen-Jarolim, H J Bax, R Bianchini, M Capron, C Corrigan, M Castells, D Dombrowicz, T R Daniels-Wells, J Fazekas, E Fiebiger, S Gatault, H J Gould, J Janda, D H Josephs, P Karagiannis, F Levi-Schaffer, A Meshcheryakova, D Mechtcheriakova, Y Mekori, F Mungenast, E A Nigro, M L Penichet, F Redegeld, L Saul, J Singer, J F Spicer, A G Siccardi, E Spillner, M C Turner, E Untersmayr, L Vangelista, S N Karagiannis
Th2 immunity and allergic immune surveillance play critical roles in host responses to pathogens, parasites and allergens. Numerous studies have reported significant links between Th2 responses and cancer, including insights into the functions of IgE antibodies and associated effector cells in both antitumour immune surveillance and therapy. The interdisciplinary field of AllergoOncology was given Task Force status by the European Academy of Allergy and Clinical Immunology in 2014. Affiliated expert groups focus on the interface between allergic responses and cancer, applied to immune surveillance, immunomodulation and the functions of IgE-mediated immune responses against cancer, to derive novel insights into more effective treatments...
June 2017: Allergy
Belen Tirado-Rodriguez, Enrique Ortega, Patricia Segura-Medina, Sara Huerta-Yepez
The transforming growth factor- β (TGF- β ) superfamily is a family of structurally related proteins that includes TGF- β , activins/inhibins, and bone morphogenic proteins (BMPs). Members of the TGF- β superfamily regulate cellular functions such as proliferation, apoptosis, differentiation, and migration and thus play key roles in organismal development. TGF- β is involved in several human diseases, including autoimmune disorders and vascular diseases. Activation of the TGF- β receptor induces phosphorylation of serine/threonine residues and triggers phosphorylation of intracellular effectors (Smads)...
2014: Journal of Immunology Research
J Singer, E Jensen-Jarolim
Passive immunotherapy with monoclonal antibodies is an indispensable cornerstone of clinical oncology. Notably, all FDA-approved antibodies comprise the IgG class, although numerous research articles proposed monoclonal antibodies of the IgM, IgG, IgA and IgE classes directed specifically against tumor-associated antigens. In particular, for the IgE isotype class, several recent studies could demonstrate high tumoricidic efficacy. Therefore, this review specifically highlights the latest developments toward IgE-based immunotherapy of cancer...
February 2014: Allergy
Erika Jensen-Jarolim, Graham Pawelec
Many intriguing relationships between allergy and cancer continue to pose important unanswered questions. Is there a correlation between IgE and atopy, and cancer? Which are the most important IgE effector cells and do they inhibit or promote tumor growth? Will IgE-mediated antigen uptake and cross-presentation by DCs activate CTLs or Tregs? What animal models are useful in this context and should we design specific anti-tumor immunotherapies, active or passive, based on IgE? Recombinant IgE has already been generated against the tumor-associated antigens folate-binding receptor, HER-2 and EGFR--how to exclude the risk of anaphylaxis in passive immunotherapy with IgE? How can we deal with hypersensitivity to antineoplastic drugs? What is the role of chemotherapeutics and biologicals in the modulation of IgE responses and the impact of the aberrant expression of mutated enzyme AID in cancer tissue? In an effort to survey the state-of-the-art in this area and to answer some of these questions, we invited leaders in the field to participate in a "Symposium-in-Writing"...
September 2012: Cancer Immunology, Immunotherapy: CII
E Jensen-Jarolim, G Achatz, M C Turner, S Karagiannis, F Legrand, M Capron, M L Penichet, J A Rodríguez, A G Siccardi, L Vangelista, A B Riemer, H Gould
Epidemiological studies have suggested inverse associations between allergic diseases and malignancies. As a proof of concept for the capability of immunoglobulin E (IgE) to destruct tumor cells, several experimental strategies have evolved to specifically target this antibody class towards relevant tumor antigens. It could be demonstrated that IgE antibodies specific to overexpressed tumor antigens have been superior to any other immunoglobulin class with respect to antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) reactions...
October 2008: Allergy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"